Scrip
Novartis's Xolair approved in EU for younger asthma patients
24 August 2009
Malini Guha
Please Login to read the full article.
24 August 2009
Malini Guha
Novartis's marketed asthma therapy, Xolair (omalizumab), has been granted European approval as an add-on therapy for severe persistent allergic asthma in children age 6 to 11 years.
The approval from the European Commission follows a positive opinion from the CHMP in July.
Xolair...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
FEATURES
- Basilea set for success as Toctino roll-out sees revenues surge
- Face-to-face: The FDA, Amgen, and its blockbuster biologic, denosumab
EVENTS
22 March 2010
London, UK
12 April 2010
Orlando, Florida
13 April 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
